Provider Briefing: Tobramycin Supply in 2026

Tobramycin — one of the most widely used aminoglycoside antibiotics in ophthalmology, infectious disease, and pulmonology — has faced intermittent supply disruptions over the past several years. For providers managing patients on this critical antibiotic, staying current on availability, cost, and alternatives is essential for continuity of care.

This article provides a comprehensive overview of the Tobramycin shortage as it stands in 2026, with actionable guidance for prescribers across specialties.

Timeline: How We Got Here

Tobramycin injection shortages have been tracked on the ASHP drug shortage database intermittently since 2015. Key milestones include:

• 2015–2019: Periodic injection shortages driven by limited generic manufacturers and manufacturing quality issues at sterile injectable facilities.
• 2020–2022: COVID-19 supply chain disruptions compounded existing vulnerabilities. Hospital demand for IV antibiotics surged during pandemic-related secondary infections.
• 2023–2024: Akorn Pharmaceuticals discontinued their Tobramycin injection (40 mg/mL, 30 mL vial), permanently removing a significant supply source. The overall active drug shortage count reached an all-time high of 323 in Q1 2024, per ASHP data.
• 2025–2026: The remaining injectable manufacturers — Pfizer, Fresenius Kabi, and Hikma — continue to supply but cannot always meet peak demand. Ophthalmic and inhaled formulations are more consistently available but not immune to disruptions.

Prescribing Implications

The supply landscape varies significantly by formulation, which has direct implications for clinical decision-making:

Injectable Tobramycin (IV/IM)

This is the most shortage-prone formulation. Hospital pharmacies may implement conservation protocols including:

• Restricting to culture-directed use rather than empiric therapy
• Prioritizing once-daily extended-interval dosing (5–7 mg/kg) to reduce total vials consumed
• Substituting Gentamicin or Amikacin when susceptibility data supports it
• Therapeutic drug monitoring to optimize dosing and minimize waste

Ophthalmic Tobramycin

Generic 0.3% drops and ointment remain generally available. However, during acute supply dips at retail pharmacies, patients may report difficulty filling prescriptions. Prescribers should be prepared to offer alternatives:

• Gentamicin 0.3% ophthalmic — same class, similar spectrum
• Moxifloxacin 0.5% (Vigamox/generic) — fluoroquinolone with broader Gram-positive coverage, less frequent dosing
• Ciprofloxacin 0.3% ophthalmic — alternative fluoroquinolone option

Inhaled Tobramycin (TOBI, Bethkis, Kitabis Pak, TOBI Podhaler)

For cystic fibrosis patients on chronic suppressive therapy for Pseudomonas aeruginosa, any supply disruption can be clinically significant. Key considerations:

• Generic inhaled Tobramycin (300 mg/5 mL for nebulization) has improved availability and is typically less expensive than TOBI brand
• TOBI Podhaler (dry powder inhaler) remains a Novartis brand product with no generic equivalent
• Aztreonam lysine (Cayston) is the primary alternative inhaled antibiotic for Pseudomonas suppression in CF
• Some CF protocols alternate TOBI and Cayston cycles, which can serve as a built-in mitigation strategy during supply disruptions

Current Availability Picture

As of early 2026:

• Tobramycin injection: Available but with intermittent allocation limits from major manufacturers. Hospital supply chains may implement rationing.
• Tobramycin ophthalmic (generic): Widely available at most retail pharmacies. Occasional spot shortages at individual locations.
• TOBI inhalation solution (brand): Available through specialty pharmacies. Novartis distribution is active.
• Generic inhaled Tobramycin: Increasingly available. Multiple manufacturers now supply this formulation.
• TOBI Podhaler (brand): Available through specialty pharmacies with Novartis support.

For real-time pharmacy-level availability data, Medfinder for Providers offers tools to help locate stock for your patients.

Cost and Access Considerations

Affordability varies dramatically by formulation and should be factored into prescribing decisions:

• Generic ophthalmic drops: $4–$10 with discount coupons (GoodRx, SingleCare). Minimal financial barrier.
• Generic injection: $4–$13 per vial. Typically covered under medical benefit in institutional settings.
• TOBI inhalation solution (brand): $8,000–$8,500+ per 28-day cycle retail. Most insured patients access through specialty pharmacy with prior authorization.
• Generic inhaled Tobramycin: $2,500–$4,000+ per 28-day cycle. Significant savings over TOBI brand.
• TOBI Podhaler: $8,000–$10,000+ per 28-day cycle. Novartis PODCARE+ Savings Card covers up to $14,000/year for commercially insured patients.

For uninsured patients, the Novartis Patient Assistance Foundation (NPAF) provides TOBI products at no cost to eligible individuals. NeedyMeds and RxAssist maintain current listings of available programs.

Tools and Resources for Your Practice

Several resources can help you and your patients navigate Tobramycin access challenges:

• Medfinder for Providers — Locate pharmacies with Tobramycin in stock and direct patients to available supply
• ASHP Drug Shortage Database — Monitor current shortage status and estimated resupply dates for injectable Tobramycin
• FDA Drug Shortage Database — Official federal shortage tracking with manufacturer supply information
• Novartis PODCARE+ — Copay assistance and patient support for TOBI Podhaler prescriptions
• Novartis Patient Assistance Foundation — Free medication for eligible uninsured patients
• CFF Compass — Cystic Fibrosis Foundation's insurance and financial assistance resource for CF patients

Looking Ahead

The Tobramycin supply outlook for 2026 and beyond is cautiously optimistic for non-injectable formulations. The entry of additional generic inhaled Tobramycin manufacturers should improve competition and availability for CF patients. However, the injectable market remains vulnerable due to the small number of sterile manufacturing facilities and the continued trend of generic injectable consolidation.

Providers should:

• Maintain familiarity with Tobramycin alternatives across all formulations
• Proactively discuss supply contingency plans with CF patients during clinic visits
• Leverage specialty pharmacy relationships to ensure uninterrupted access to inhaled products
• Use Medfinder for Providers to direct patients to pharmacies with current stock

For patient-facing information you can share, see our article: Tobramycin shortage update: What patients need to know in 2026.

Final Thoughts

Tobramycin remains a clinically essential antibiotic across multiple specialties. While supply disruptions in 2026 are manageable with proactive planning, providers play a critical role in ensuring patients maintain access — through timely prescribing, awareness of alternatives, and use of tools like Medfinder to bridge availability gaps.

For a practical workflow guide on helping patients locate Tobramycin, see our companion article: How to help your patients find Tobramycin in stock.